Healthcare Tribune France: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Tribune France.

Press releases published on July 1, 2026

Jul. 1, 2026

Amoéba has received marketing authorization in France for its biofungicide AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Amoéba obtient l’autorisation de mise sur le marché en France pour son biofongicide AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Amoéba verkrijgt in Frankrijk een vergunning voor het in de handel brengen van zijn biofungicide AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Amoéba obtém autorização de colocação no mercado em França para o seu biofungicida AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Amoéba obtiene la autorización de comercialización en Francia para su biofungicida AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Amoéba ottiene l’autorizzazione all'immissione in commercio in Francia per il suo biofungicida AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Press Release: Availability of the aide-mémoire for Q2 2026 results

Indeterminate GlobeNewswire

Jul. 1, 2026

Communiqué de presse : Mise en ligne du document «Q2 2026 aide-mémoire »

Indeterminate GlobeNewswire

Jul. 1, 2026

Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment

Indeterminate GlobeNewswire

Jul. 1, 2026

Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé

Indeterminate GlobeNewswire

Jul. 1, 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Indeterminate GlobeNewswire

Jul. 1, 2026

Ipsen va acquérir Memo Therapeutics AG, élargissant son portefeuille de maladies rares grâce à l’ajout d’un anticorps premier de sa classe ciblant le polyomavirus BK  

Indeterminate GlobeNewswire